Oral Antifungal Agents and Drug-Induced Liver Injury in Taiwan
This paper reviews a large-scale Taiwanese cohort study investigating the incidence and risk factors of drug-induced liver injury (DILI) associated with oral antifungal agent use. Drawing on the National Health Insurance Longitudinal Health Insurance Database (2002–2008), the study examined over 90,000 patients treated with one of five agents — griseofulvin, fluconazole, itraconazole, ketoconazole, or terbinafine — and compared outcomes against a control group. The review summarizes key findings including incidence rates, mortality data, the elevated relative risk of DILI among antifungal users, and the role of age and treatment duration as risk factors, while evaluating the study's clinical relevance, methodological strengths, and limitations.
- Introduction and Clinical Significance of DILI: DILI as a global health problem and its impact in Taiwan
- Study Population and Methodology: Database, cohort selection, and five antifungal agents studied
- Incidence Rates by Agent and Treatment Duration: Varying DILI rates by antifungal type and treatment length
- Key Outcomes: Hospitalization, Mortality, and Relative Risk: Fifty hospitalizations, six deaths, and elevated relative risk
- Strengths, Limitations, and Clinical Implications: Study appraisal, limitations, and practical relevance
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The review closely tracks the structure of the source study, moving logically from background and clinical significance through methodology, results, and appraisal.
- Quantitative findings are cited precisely — incidence rates per 10,000 patients, relative risk values, mean ages — grounding the summary in verifiable data rather than vague characterizations.
- The conclusion balances praise for the study's strengths (large sample, multi-agent scope, broad population coverage) with honest acknowledgment of its limitations, demonstrating critical reading skills.
Key academic technique demonstrated
The paper models concise but data-faithful article summarization. Rather than paraphrasing loosely, it preserves specific numerical findings (e.g., fluconazole incidence of 31.6/10,000; adjusted relative risk of 2.38) while situating them within the study's broader clinical and public-health context. This precision is essential in health-sciences writing, where misrepresenting effect sizes can mislead readers.
Structure breakdown
The paper opens by establishing why DILI matters globally and in Taiwan specifically, including the patient-behavior consequence of fear-driven treatment refusal. It then describes the database and cohort design, presents incidence and outcome data by agent, reports mortality and relative-risk findings, and closes with a balanced appraisal of the study's contributions and limitations. Five clearly defined sections support easy navigation of a data-dense topic.
Introduction and Clinical Significance of DILI
Kao et al. open their study by asserting that drug-induced liver injury (DILI) is the most common cause of acute liver failure in the United States and a major issue in other countries as well. DILI is a serious health problem with significant ramifications for physicians, patients, the pharmaceutical industry, and government regulators. The use of oral antifungal agents has resulted in several well-publicized cases of serious liver injuries leading to death, even though the incidence rates of DILI overall remain low.
The clinical significance of this concern is reflected in patient behavior. Almost half of patients in Taiwan infected with onychomycosis refuse treatment with oral antifungal agents because of concerns about potential liver injury. Despite this, no prior study had examined antifungal-agent-induced DILI specifically in the Taiwanese population. The current study therefore aimed to examine the incidence of liver injuries associated with oral antifungal use in Taiwan and to identify the risk factors for adverse liver outcomes in Taiwanese patients who use these agents.
Study Population and Methodology
The Longitudinal Health Insurance Database (covering the years 2002–2008) was utilized from Taiwan's National Health Insurance program, which covers more than 98% of the country's population. A total of 90,847 patients who had used antifungal agents were identified, of whom 69,665 were compared to a randomly extracted control group of 82,300 patients. Five oral antifungal agents were investigated in the study: griseofulvin, fluconazole, itraconazole, ketoconazole, and terbinafine.
The large, nationally representative database provided a robust foundation for examining DILI incidence across different agents, treatment durations, and patient subgroups. Adjustments were made for demographic variables including age and gender, as well as comorbid medical conditions such as hypertension, diabetes, hyperlipidemia, cardiovascular disease, chronic renal disease, and hepatitis B or C.
Incidence Rates by Agent and Treatment Duration
There was some variance in the incidence rates of DILI among patients using oral antifungal agents across the study period, ranging from 1.58 to 8.39 per 10,000 patients per year over the eight years examined. Incidence rates also varied by the type of oral antifungal agent used. Fluconazole had the highest incidence rate (31.6 per 10,000), while terbinafine had the lowest (1.6 per 10,000).
The incidence rate of adverse liver outcomes increased for most antifungal agents as treatment duration lengthened. Ketoconazole had the highest incidence rate under conditions of prolonged treatment, highlighting the importance of monitoring patients on extended antifungal regimens. These findings underscore the need for clinicians to weigh treatment duration carefully when prescribing these agents, particularly for patients with additional risk factors.
Create your account
Always verify citation format against your institution’s current style guide requirements.